Allergy Therapeutics plc provided earnings guidance for the fiscal year ending June 2023. For the period, the company expects the revenue will be between approximately 13% and 18% lower than market expectations of circa £80 million at current exchange rates.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5.25 GBX | +0.96% | +34.62% | +110.00% |
1st Jan change | Capi. | |
---|---|---|
+110.00% | 320M | |
+19.33% | 125B | |
+13.95% | 108B | |
-3.53% | 24.57B | |
+3.64% | 22.82B | |
-9.95% | 18.19B | |
-41.48% | 16.54B | |
-12.62% | 16.5B | |
+0.99% | 13.39B | |
+21.79% | 11.1B |
- Stock Market
- Equities
- AGY Stock
- News Allergy Therapeutics plc
- Allergy Therapeutics plc Provides Earnings Guidance for the Fiscal Year Ending June 2023